INCENDIA THERAPEUTICS Trademark

Trademark Overview


On Tuesday, December 12, 2023, a trademark application was filed for INCENDIA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the INCENDIA THERAPEUTICS trademark a serial number of 98311406. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, February 18, 2026. This trademark is owned by Incendia Therapeutics Inc.. The INCENDIA THERAPEUTICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Monoclonal antibodies used in industry and science, and in the manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the treatment of immune-excluded tumors found in recalcitrant cancers

Drug discovery services for the discovery of monoclonal antibody-containing drugs for the treatment of immune-excluded tumors, provided through a computational platform engine using biology and chemistry analytics in the field of recalcitrant cancers

Monoclonal antibody products and preparations for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical products and preparations consisting of monoclonal antibodies for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical preparations developed with a computational platform engine using biology and chemistry analytics for the treatment of immune-excluded tumors found in recalcitrant cancers
incendia therapeutics

General Information


Serial Number98311406
Word MarkINCENDIA THERAPEUTICS
Filing DateTuesday, December 12, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, February 18, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesMonoclonal antibodies used in industry and science, and in the manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the treatment of immune-excluded tumors found in recalcitrant cancers
Goods and ServicesDrug discovery services for the discovery of monoclonal antibody-containing drugs for the treatment of immune-excluded tumors, provided through a computational platform engine using biology and chemistry analytics in the field of recalcitrant cancers
Goods and ServicesMonoclonal antibody products and preparations for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical products and preparations consisting of monoclonal antibodies for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical preparations developed with a computational platform engine using biology and chemistry analytics for the treatment of immune-excluded tumors found in recalcitrant cancers

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, December 12, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIncendia Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02135

Trademark Events


Event DateEvent Description
Tuesday, December 12, 2023NEW APPLICATION ENTERED
Sunday, March 17, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 11, 2024ASSIGNED TO EXAMINER
Friday, July 12, 2024NON-FINAL ACTION WRITTEN
Friday, July 12, 2024NON-FINAL ACTION E-MAILED
Friday, July 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 9, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, October 9, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, December 13, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 13, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 22, 2025FINAL REFUSAL WRITTEN
Wednesday, January 22, 2025FINAL REFUSAL E-MAILED
Wednesday, January 22, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, April 14, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, April 14, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, July 17, 2025EXPARTE APPEAL RECEIVED AT TTAB
Thursday, July 17, 2025JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, July 17, 2025EX PARTE APPEAL-INSTITUTED
Thursday, July 17, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, July 22, 2025ASSIGNED TO LIE
Tuesday, July 22, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 22, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 18, 2026NON-FINAL ACTION WRITTEN
Wednesday, February 18, 2026NON-FINAL ACTION E-MAILED
Wednesday, February 18, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED